Henrike Feuersenger
Marburg An Der Lahn, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.
Journal: The Journal of allergy and clinical immunology
Published: April 08, 2025
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Journal: The Lancet. Haematology
Published: January 09, 2024
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: January 23, 2023
Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
Journal: Allergy and asthma proceedings
Published: May 07, 2022
A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
Journal: Clinical and translational science
Published: June 30, 2021
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: May 14, 2021
Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters.
Journal: Thrombosis and haemostasis
Published: November 17, 2020
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: March 13, 2020
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Journal: Pediatric allergy, immunology, and pulmonology
Published: January 14, 2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: December 16, 2019
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: April 11, 2019
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.
Journal: The journal of allergy and clinical immunology. In practice
Published: November 05, 2018
Last Updated: 09/26/2026